Literature DB >> 24720592

The utility of metformin therapy in reproductive-aged women with polycystic ovary syndrome (PCOS).

Nisha Nathan, Shannon D Sullivan1.   

Abstract

Metformin, an insulin-sensitizing drug commonly used to treat Type 2 Diabetes Mellitus (T2DM), has been increasingly used off-label for the treatment of polycystic ovary syndrome (PCOS), which affects at least 5-10% of reproductive- age women. With very little risk associated with its use, metformin provides many important benefits to women with PCOS, including regulating menstrual cycles, improving clinical signs of hyperandrogenism, ameliorating metabolic syndrome, inducing ovulation, improving pregnancy rates and pregnancy outcomes, preventing gestational diabetes, and preventing progression to T2DM. Here, we review the indications for metformin in women with PCOS, with a focus on the use of metformin during pre-conception and pregnancy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24720592     DOI: 10.2174/1389201015666140330195142

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  4 in total

1.  Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study.

Authors:  Joanne E Given; Maria Loane; Ester Garne; Marie-Claude Addor; Marian Bakker; Bénédicte Bertaut-Nativel; Miriam Gatt; Kari Klungsoyr; Nathalie Lelong; Margery Morgan; Amanda J Neville; Anna Pierini; Anke Rissmann; Helen Dolk
Journal:  BMJ       Date:  2018-06-25

2.  Short chain fatty acid, acetate restores ovarian function in experimentally induced PCOS rat model.

Authors:  Kehinde S Olaniyi; Al-Amin M Bashir; Stephanie E Areloegbe; Isaiah W Sabinari; Christopher O Akintayo; Adesola A Oniyide; Ayodeji Aturamu
Journal:  PLoS One       Date:  2022-07-26       Impact factor: 3.752

3.  Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells.

Authors:  Emuejevoke Olokpa; Sammed N Mandape; Siddharth Pratap; La Monica V Stewart
Journal:  BMC Cancer       Date:  2022-09-29       Impact factor: 4.638

4.  Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.

Authors:  Miguel A Sanchez-Garrido; Manuel Tena-Sempere
Journal:  Mol Metab       Date:  2020-02-05       Impact factor: 7.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.